Syngene International Ltd., a Bengaluru-based integrated research, development, and manufacturing services provider, reported a 14.5% year-on-year (YoY) increase in consolidated net profit for the quarter ended June 30, 2025 (Q1 FY26). The company posted a net profit of INR 86.7 crore, up from INR 75.7 crore in the same period last fiscal.

Operational revenue grew by 10.7% to INR 874.5 crore from INR 789.7 crore in Q1 FY25. EBITDA for the quarter rose 19% to INR 224 crore, compared to INR 188 crore last year. The EBITDA margin improved to 25%, up from 23% a year ago.

Peter Bains, Managing Director and CEO, expressed satisfaction with the Q1 performance, stating, “We are pleased with the growth performance in the first quarter, which is aligned with our expectations.” He highlighted that the sustained conversion of pilot programs into long-term contracts in the Research Services division was a key growth driver.

The company also noted progress in its biologics manufacturing division, with the commencement of operations at its new Unit III facility in Bengaluru. Preparations are underway to launch operations at the Bayview facility in the US later this year. Bains added, “We continued to strengthen and expand our scientific capabilities, including the launch of a state-of-the-art dedicated peptide laboratory.”

Despite broader macroeconomic uncertainties, Syngene maintains a confident outlook for FY26.

Chief Financial Officer Deepak Jain noted that the Q1 profit includes a tax benefit from the transfer of gratuity funds to the Employee Gratuity Trust. “We remain on track to meet our full-year guidance while closely monitoring market trends,” Jain said.

On the regulatory front, Syngene successfully completed a US FDA Good Clinical Practices (GCP) inspection of its Human Pharmacology Unit with no observations. Additionally, its Biologics facility at Biocon Park received an Establishment Inspection Report (EIR) with a favourable Voluntary Action Indicated (VAI) outcome. The company also underwent over 20 client and regulatory audits during the quarter, reaffirming its focus on quality and compliance.